首页 > 最新文献

Breast disease最新文献

英文 中文
Synchronous primary breast angiosarcoma with invasive ductal carcinoma. 原发性乳腺血管肉瘤与浸润性导管癌同步。
Pub Date : 2024-01-01 DOI: 10.3233/BD-240003
Wala Ben Kridis, Mayssa Lajnef, Afef Khanfir

Primary angiosarcoma (PAS) of the breast is an extremely uncommon variant of breast malignancies. Highly aggressiveness and dismal prognosis characterize this endothelial neoplasm. We report here an unusual case of PAS of the breast occurring in a 46-year-old woman associated with concurrent bilateral invasive ductal carcinoma and ovarian metastases.

乳腺原发性血管肉瘤(PAS)是乳腺恶性肿瘤中极为罕见的一种。这种内皮肿瘤具有高度侵袭性和预后不良的特点。我们在此报告了一例不同寻常的乳腺原发性血管肉瘤病例,患者为一名 46 岁女性,同时伴有双侧浸润性导管癌和卵巢转移。
{"title":"Synchronous primary breast angiosarcoma with invasive ductal carcinoma.","authors":"Wala Ben Kridis, Mayssa Lajnef, Afef Khanfir","doi":"10.3233/BD-240003","DOIUrl":"10.3233/BD-240003","url":null,"abstract":"<p><p>Primary angiosarcoma (PAS) of the breast is an extremely uncommon variant of breast malignancies. Highly aggressiveness and dismal prognosis characterize this endothelial neoplasm. We report here an unusual case of PAS of the breast occurring in a 46-year-old woman associated with concurrent bilateral invasive ductal carcinoma and ovarian metastases.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11492004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142280459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expression and promoter methylation of mitogen-activated protein kinase 1 in tumor and marginal cells of breast cancer 乳腺癌肿瘤细胞和边缘细胞中丝裂原活化蛋白激酶 1 的表达和启动子甲基化情况
Pub Date : 2023-12-22 DOI: 10.3233/bd-230001
Solmaz Goldoost, H. Zarredar, M. Asadi, Milad Shirvaliloo, M. Raeisi
AIM: In the present study, we sought to explore potential differences in the expression and promoter methylation of mitogen-activated protein kinase 1 (MAPK1) between tumor and marginal cells of breast cancer lesions. METHODS: A total of 50 randomly selected patients with breast cancer (BCa) undergoing needle biopsy were enrolled. Clinical specimens containing both tumor and marginal cells were collected and preserved. After DNA extraction using specific primers, MAPK1 mRNA and promoter methylation were measured with spectrophotometry at 260/280 nm absorption wavelengths. To deliver a comparative analysis, data from The Cancer Genome Atlas (TCGA) program regarding breast cancer (BRCA), were downloaded from Xena Functional Genomics Explorer and separately analyzed. The suitability of MAPK1 expression and promoter methylation as biomarkers for BCa was analyzed with receiver operating characteristic (ROC) curves. RESULTS: We found a positive correlation between tumor stage and MAPK1 expression (P-value: 0.029) in BCa. Likewise, MAPK1 expression was significantly associated with lymph node metastasis (P-value: 0.018). There was a significant difference in the expression of MAPK1 mRNA between tumor and marginal cells of BCa and BRCA (P-value < 0.001). However, we did not find any statistically significant difference in MAPK1 promoter methylation between tumor and marginal cells of both BCa and BRCA. With an area under the curve (AUC) of 0.71, the diagnostic accuracy of MAPK1 expression in BCa and BRCA was validated. However, MAPK1 promoter methylation was not found to be a suitable biomarker. CONCLUSION: Our findings suggest that while MAPK1 expression, might be a promising biomarker for evaluating oncogenic activity in patients suspected of BCa. We were not able to detect a prognostic/diagnostic role for MAPK1 promoter methylation.
目的:在本研究中,我们试图探讨乳腺癌病灶的肿瘤细胞和边缘细胞在丝裂原活化蛋白激酶 1 (MAPK1) 的表达和启动子甲基化方面的潜在差异。方法:我们随机选取了 50 名接受针刺活检的乳腺癌(BCa)患者。收集并保存含有肿瘤细胞和边缘细胞的临床标本。使用特定引物提取 DNA 后,用分光光度法在 260/280 纳米吸收波长下测量 MAPK1 mRNA 和启动子甲基化。为了进行比较分析,还从 Xena Functional Genomics Explorer 中下载了癌症基因组图谱(TCGA)计划中有关乳腺癌(BRCA)的数据,并分别进行了分析。用接收者操作特征曲线(ROC)分析了 MAPK1 表达和启动子甲基化作为 BCa 生物标志物的适宜性。结果:我们发现在 BCa 中,肿瘤分期与 MAPK1 表达呈正相关(P 值:0.029)。同样,MAPK1的表达与淋巴结转移也显著相关(P值:0.018)。BCa 和 BRCA 的肿瘤细胞和边缘细胞的 MAPK1 mRNA 表达存在明显差异(P 值<0.001)。然而,我们没有发现 BCa 和 BRCA 的肿瘤细胞和边缘细胞的 MAPK1 启动子甲基化有任何统计学上的显著差异。曲线下面积(AUC)为 0.71,验证了 MAPK1 在 BCa 和 BRCA 中表达的诊断准确性。然而,MAPK1 启动子甲基化并不是一个合适的生物标记物。结论:我们的研究结果表明,MAPK1表达可能是评估疑似BCa患者致癌活性的一种有前途的生物标志物。我们未能发现 MAPK1 启动子甲基化在预后/诊断方面的作用。
{"title":"Expression and promoter methylation of mitogen-activated protein kinase 1 in tumor and marginal cells of breast cancer","authors":"Solmaz Goldoost, H. Zarredar, M. Asadi, Milad Shirvaliloo, M. Raeisi","doi":"10.3233/bd-230001","DOIUrl":"https://doi.org/10.3233/bd-230001","url":null,"abstract":"AIM: In the present study, we sought to explore potential differences in the expression and promoter methylation of mitogen-activated protein kinase 1 (MAPK1) between tumor and marginal cells of breast cancer lesions. METHODS: A total of 50 randomly selected patients with breast cancer (BCa) undergoing needle biopsy were enrolled. Clinical specimens containing both tumor and marginal cells were collected and preserved. After DNA extraction using specific primers, MAPK1 mRNA and promoter methylation were measured with spectrophotometry at 260/280 nm absorption wavelengths. To deliver a comparative analysis, data from The Cancer Genome Atlas (TCGA) program regarding breast cancer (BRCA), were downloaded from Xena Functional Genomics Explorer and separately analyzed. The suitability of MAPK1 expression and promoter methylation as biomarkers for BCa was analyzed with receiver operating characteristic (ROC) curves. RESULTS: We found a positive correlation between tumor stage and MAPK1 expression (P-value: 0.029) in BCa. Likewise, MAPK1 expression was significantly associated with lymph node metastasis (P-value: 0.018). There was a significant difference in the expression of MAPK1 mRNA between tumor and marginal cells of BCa and BRCA (P-value < 0.001). However, we did not find any statistically significant difference in MAPK1 promoter methylation between tumor and marginal cells of both BCa and BRCA. With an area under the curve (AUC) of 0.71, the diagnostic accuracy of MAPK1 expression in BCa and BRCA was validated. However, MAPK1 promoter methylation was not found to be a suitable biomarker. CONCLUSION: Our findings suggest that while MAPK1 expression, might be a promising biomarker for evaluating oncogenic activity in patients suspected of BCa. We were not able to detect a prognostic/diagnostic role for MAPK1 promoter methylation.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138944204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Course of objectively measured physical activity and sleep in postmenopausal breast cancer survivors during the COVID-19 pandemic: A 1-year follow-up COVID-19 大流行期间绝经后乳腺癌幸存者客观测量的体力活动和睡眠情况:为期一年的随访
Pub Date : 2023-12-20 DOI: 10.3233/bd-230049
Sandra J M van Cappellen-van Maldegem, M. Hoedjes, Michiel R. de Boer, Inge Nijman, Henrike M.W. van Valenberg, Jacob C. Seidell, L. V. van de Poll-Franse, L. Buffart, F. Mols, B. D. de Rooij
BACKGROUND: As physical inactivity and poor sleep quality may impose additional risk for cancer recurrence and overall mortality in postmenopausal breast cancer (PMBC) survivors, it is important to gain insight into the effect of the COVID-19 pandemic on their physical activity (PA) and sleep level. OBJECTIVE: This study aimed to assess the course of their physical activity (PA) and sleep throughout governmental measures against COVID-19 during 12 months of the COVID-19 pandemic. METHODS: PMBC survivors (n = 96) wore an ActiGraph wGT3X-BT for seven consecutive days at 12 and 18 months after diagnosis and additional measurements were taken after onset of the second (partial) COVID-19 lockdown. Longitudinal data was categorized into four timepoints: before onset of COVID-19 (T1), during the initial lockdown (T2), in between initial and second lockdown (T3), and during the second lockdown (T4). General linear mixed effects models assessed differences in moderate-to-vigorous physical activity (MVPA) per day, total minutes of PA per day, average acceleration, intensity gradient, sleep efficiency, and sleep duration over time. RESULTS: Levels of MVPA per day before COVID-19 were low (Median = 20.9 min/day (IQR = 10.8;36.2)), and time spent physically active was most often in light intensity, which remained stable throughout the pandemic. Sleep duration (Median = 442.8 min/night (IQR = 418.3;478.0)) and efficiency (85.9% (IQR = 79.6;88.4)) was sufficient before COVID-19 and showed stability over time. CONCLUSIONS: Low levels of PA with mostly light intensity, and adequate sleep efficiency and duration were observed before COVID in PMBC survivors. This was not further affected by COVID-19 governmental measures.
背景:由于缺乏运动和睡眠质量差可能会增加绝经后乳腺癌(PMBC)幸存者癌症复发和总死亡率的风险,因此深入了解 COVID-19 大流行对她们的体力活动(PA)和睡眠水平的影响非常重要。目的:本研究旨在评估在 COVID-19 大流行的 12 个月期间,政府针对 COVID-19 所采取的措施对其体力活动 (PA) 和睡眠的影响。方法:PMBC 幸存者(n = 96)在确诊后 12 个月和 18 个月连续 7 天佩戴 ActiGraph wGT3X-BT,并在 COVID-19 第二次(部分)封锁开始后进行额外测量。纵向数据分为四个时间点:COVID-19 发病前(T1)、首次锁定期间(T2)、首次锁定和第二次锁定之间(T3)以及第二次锁定期间(T4)。一般线性混合效应模型评估了每天中等强度体力活动(MVPA)、每天体力活动总分钟数、平均加速度、强度梯度、睡眠效率和睡眠时间随时间变化的差异。结果:COVID-19 之前的每天中强度体力活动水平较低(中位数 = 20.9 分钟/天(IQR = 10.8;36.2)),体力活动时间最常为轻度,在整个大流行期间保持稳定。睡眠时间(中位数 = 442.8 分钟/晚(IQR = 418.3;478.0))和睡眠效率(85.9%(IQR = 79.6;88.4))在 COVID-19 之前是充足的,随着时间的推移保持稳定。结论:在 COVID 之前,PMBC 存活者的 PA 水平较低,大部分为轻度 PA,睡眠效率和睡眠时间充足。COVID-19 的政府措施并未对此产生进一步影响。
{"title":"Course of objectively measured physical activity and sleep in postmenopausal breast cancer survivors during the COVID-19 pandemic: A 1-year follow-up","authors":"Sandra J M van Cappellen-van Maldegem, M. Hoedjes, Michiel R. de Boer, Inge Nijman, Henrike M.W. van Valenberg, Jacob C. Seidell, L. V. van de Poll-Franse, L. Buffart, F. Mols, B. D. de Rooij","doi":"10.3233/bd-230049","DOIUrl":"https://doi.org/10.3233/bd-230049","url":null,"abstract":"BACKGROUND: As physical inactivity and poor sleep quality may impose additional risk for cancer recurrence and overall mortality in postmenopausal breast cancer (PMBC) survivors, it is important to gain insight into the effect of the COVID-19 pandemic on their physical activity (PA) and sleep level. OBJECTIVE: This study aimed to assess the course of their physical activity (PA) and sleep throughout governmental measures against COVID-19 during 12 months of the COVID-19 pandemic. METHODS: PMBC survivors (n = 96) wore an ActiGraph wGT3X-BT for seven consecutive days at 12 and 18 months after diagnosis and additional measurements were taken after onset of the second (partial) COVID-19 lockdown. Longitudinal data was categorized into four timepoints: before onset of COVID-19 (T1), during the initial lockdown (T2), in between initial and second lockdown (T3), and during the second lockdown (T4). General linear mixed effects models assessed differences in moderate-to-vigorous physical activity (MVPA) per day, total minutes of PA per day, average acceleration, intensity gradient, sleep efficiency, and sleep duration over time. RESULTS: Levels of MVPA per day before COVID-19 were low (Median = 20.9 min/day (IQR = 10.8;36.2)), and time spent physically active was most often in light intensity, which remained stable throughout the pandemic. Sleep duration (Median = 442.8 min/night (IQR = 418.3;478.0)) and efficiency (85.9% (IQR = 79.6;88.4)) was sufficient before COVID-19 and showed stability over time. CONCLUSIONS: Low levels of PA with mostly light intensity, and adequate sleep efficiency and duration were observed before COVID in PMBC survivors. This was not further affected by COVID-19 governmental measures.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138953766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Conventional standard-sized bra with prosthesis or patient’s bra with customized hand-knitted external prosthesis after mastectomy: Mixed-methods evaluation of patients’ preferences 乳房切除术后使用带假体的传统标准尺寸胸罩还是带定制手工编织外部假体的患者胸罩:对患者偏好的混合方法评估
Pub Date : 2023-12-08 DOI: 10.3233/bd-230040
R. P. Ng, John C. Allen, Yen-Yen Chia, Geok Hoon Lim
INTRODUCTION: In breast cancer patients undergoing mastectomy without reconstruction, an external breast prosthesis could aid patients’ recovery, improve body image and confidence by helping to regain a symmetrical chest appearance when dressed. However, external breast prosthesis preferences among Asian breast cancer patients were not widely studied. We aimed to compare patients’ experience with the conventional commercially manufactured standard-sized (small, medium, large, extra-large) bra and prosthesis versus customized hand-knitted external breast prosthesis with patient’s bra after unilateral mastectomy at a tertiary hospital. This is the first such study in Asian women, to our knowledge. METHODS: In this prospective study, participants used the conventional bra-prosthesis followed by the customized one consecutively, each for at least 3 months before they were administered an identical questionnaire at 3 and 6 months respectively. The questionnaire assessed the patients’ experience with the prosthesis on the aspects of comfort, body image and satisfaction etc. Patients were also invited for in-depth interviews. RESULTS: Of 155 eligible patients, 148 patients participated with a response rate of 95.5%. 99 (67%) participants preferred the customized prosthesis, while 38 (25.7%) did not. 11 (7.4%) participants were undecided. Seventeen participants underwent in-depth interviews until data saturation on major qualitative themes was achieved. More patients experienced excessive sweating (p < 0.0001), greater discomfort (p = 0.0195) and higher rates of prosthesis dislodgement (p = 0.0269) with the conventional bra-prosthesis. CONCLUSION: Customized external breast prostheses could be an alternative to the conventional ones for breast cancer patients with mastectomy, with additional benefits of less sweating, more comfort and less dislodgement perceived.
简介:在接受乳房切除术而不进行乳房重建的乳腺癌患者中,外部乳房假体可以帮助患者恢复,通过帮助患者恢复穿着时对称的胸部外观来改善身体形象和信心。然而,亚洲乳腺癌患者对外部乳房假体的偏好并没有广泛的研究。我们的目的是比较某三级医院单侧乳房切除术后,患者使用传统商业生产的标准尺寸(小、中、大、特大)胸罩和假体与定制的手工编织外乳房假体与患者胸罩的体验。据我们所知,这是第一次在亚洲女性中进行这样的研究。方法:在这项前瞻性研究中,参与者连续使用常规假体和定制假体,每个假体至少使用3个月,然后分别在第3个月和第6个月进行相同的问卷调查。问卷从舒适性、身体形象、满意度等方面评价患者使用义肢的体验。患者也被邀请进行深度访谈。结果:155例符合条件的患者中,148例患者参与,有效率为95.5%。99人(67%)喜欢定制义肢,38人(25.7%)不喜欢定制义肢。11名(7.4%)参与者尚未决定。17名参与者接受了深入访谈,直到在主要定性主题上达到数据饱和。使用传统的文胸假体时,更多的患者出现出汗过多(p < 0.0001),更大的不适(p = 0.0195)和更高的假体脱位率(p = 0.0269)。结论:定制乳房外假体可替代传统乳房外假体用于乳腺癌切除术患者,具有出汗少、舒适、移位少等优点。
{"title":"Conventional standard-sized bra with prosthesis or patient’s bra with customized hand-knitted external prosthesis after mastectomy: Mixed-methods evaluation of patients’ preferences","authors":"R. P. Ng, John C. Allen, Yen-Yen Chia, Geok Hoon Lim","doi":"10.3233/bd-230040","DOIUrl":"https://doi.org/10.3233/bd-230040","url":null,"abstract":"INTRODUCTION: In breast cancer patients undergoing mastectomy without reconstruction, an external breast prosthesis could aid patients’ recovery, improve body image and confidence by helping to regain a symmetrical chest appearance when dressed. However, external breast prosthesis preferences among Asian breast cancer patients were not widely studied. We aimed to compare patients’ experience with the conventional commercially manufactured standard-sized (small, medium, large, extra-large) bra and prosthesis versus customized hand-knitted external breast prosthesis with patient’s bra after unilateral mastectomy at a tertiary hospital. This is the first such study in Asian women, to our knowledge. METHODS: In this prospective study, participants used the conventional bra-prosthesis followed by the customized one consecutively, each for at least 3 months before they were administered an identical questionnaire at 3 and 6 months respectively. The questionnaire assessed the patients’ experience with the prosthesis on the aspects of comfort, body image and satisfaction etc. Patients were also invited for in-depth interviews. RESULTS: Of 155 eligible patients, 148 patients participated with a response rate of 95.5%. 99 (67%) participants preferred the customized prosthesis, while 38 (25.7%) did not. 11 (7.4%) participants were undecided. Seventeen participants underwent in-depth interviews until data saturation on major qualitative themes was achieved. More patients experienced excessive sweating (p < 0.0001), greater discomfort (p = 0.0195) and higher rates of prosthesis dislodgement (p = 0.0269) with the conventional bra-prosthesis. CONCLUSION: Customized external breast prostheses could be an alternative to the conventional ones for breast cancer patients with mastectomy, with additional benefits of less sweating, more comfort and less dislodgement perceived.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138589492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can paternal environmental experiences affect the breast cancer risk in offspring? A systematic review 父亲的环境经历会影响后代患乳腺癌的风险吗?系统回顾
Pub Date : 2023-12-06 DOI: 10.3233/bd-220062
Najmeh Bagher Hosseini, Sara Moosapour, Haniyeh Bashi Zadeh Fakhar, Afshin Ryan Nazari, Maryam Omrani Hasehmi, Fatemeh Hadavand, Mohammad Seraj, M. Akbari
INTRODUCTION: Studies in recent years have shown that parental environmental experiences can affect their offspring’s risk of breast cancer (BC). We assessed the effect of different paternal factors on BC risk in offspring by reviewing the existing literature. METHOD: This systematic review followed the Joanna Briggs Institute’s (JBI) method for systematic reviews of qualitative evidence. The primary keywords were searched in reliable databases such as PubMed, Google Scholar, Elsevier, SID, and Wiley in English until 31 December 2021. Two authors independently examined the articles in terms of inclusion criteria and quality assessment of the articles. RESULTS: Of the 438 studies, 19 met the inclusion criteria of this systematic review and were included in the study. Paternal factors investigated in these studies included age at delivery, diet, occupational exposures, occupation type and education. The reported relationships between these factors and breast cancer varied among different studies. CONCLUSION: Studies considered in this article show that fathers’ age at the time of delivery of the child, dietary habits, overweight and occupational factors can affect the incidence of BC risk in the next generation.
近年来的研究表明,父母的环境经历会影响其后代患乳腺癌(BC)的风险。我们通过回顾现有文献来评估不同父亲因素对后代BC风险的影响。方法:本系统评价采用乔安娜布里格斯研究所(JBI)的定性证据系统评价方法。主要关键词在PubMed、Google Scholar、Elsevier、SID和Wiley等可靠的英文数据库中搜索,直到2021年12月31日。两位作者根据纳入标准和文章的质量评估独立检查了这些文章。结果:在438项研究中,有19项符合本系统评价的纳入标准并被纳入本研究。这些研究调查的父亲因素包括出生年龄、饮食、职业暴露、职业类型和教育程度。这些因素与乳腺癌之间的关系在不同的研究中有所不同。结论:本文考虑的研究表明,父亲分娩时的年龄、饮食习惯、体重超重和职业因素会影响下一代BC风险的发生。
{"title":"Can paternal environmental experiences affect the breast cancer risk in offspring? A systematic review","authors":"Najmeh Bagher Hosseini, Sara Moosapour, Haniyeh Bashi Zadeh Fakhar, Afshin Ryan Nazari, Maryam Omrani Hasehmi, Fatemeh Hadavand, Mohammad Seraj, M. Akbari","doi":"10.3233/bd-220062","DOIUrl":"https://doi.org/10.3233/bd-220062","url":null,"abstract":"INTRODUCTION: Studies in recent years have shown that parental environmental experiences can affect their offspring’s risk of breast cancer (BC). We assessed the effect of different paternal factors on BC risk in offspring by reviewing the existing literature. METHOD: This systematic review followed the Joanna Briggs Institute’s (JBI) method for systematic reviews of qualitative evidence. The primary keywords were searched in reliable databases such as PubMed, Google Scholar, Elsevier, SID, and Wiley in English until 31 December 2021. Two authors independently examined the articles in terms of inclusion criteria and quality assessment of the articles. RESULTS: Of the 438 studies, 19 met the inclusion criteria of this systematic review and were included in the study. Paternal factors investigated in these studies included age at delivery, diet, occupational exposures, occupation type and education. The reported relationships between these factors and breast cancer varied among different studies. CONCLUSION: Studies considered in this article show that fathers’ age at the time of delivery of the child, dietary habits, overweight and occupational factors can affect the incidence of BC risk in the next generation.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138595078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Eribulin in metastatic breast cancer: Real world data 转移性乳腺癌中的 Eribulin:真实世界数据
Pub Date : 2023-12-05 DOI: 10.3233/bd-230031
C. L. Fernández-Laguna, I. Maray, Lola Macia-Rivas, Cristina Álvarez-Asteinza, Sergio Fernández-Lastras, Veronica Velasco Durántez, Mónica Carbajales Álvarez, Ana Lozan-Blázquez
BACKGROUND: Metastatic breast cancer (MBC) is incurable. Systemic therapy is the standard treatment; however, an optimal sequence of chemotherapy has not been established. OBJECTIVE: Evaluating effectiveness and safety of eribulin in MBC treatment and comparing the results obtained with published literature. METHODS: Observational, descriptive and retrospective study of patients with MBC treated with eribulin from 01/12/2015 to 30/10/2021. Effectiveness was analysed using Kaplan–Meier-survival-curves, for the overall number of patients treated and stratified by treatment line. Safety was measured according to adverse events (AE) based on CTCAE v5.0. Data analysis was performed using R v4.0.1. RESULTS: They were included in this study 53 women who received eribulin (median age 58 years). Comparison of median survival from this study versus published data were: progression-free-survival (PFS) 3 (IC95%: 3–4) versus 3.7 months and overall-survival (OS) 8 (IC95%: 3–4) versus 13.2 months for the overall number of patients. For the 1–3 line treatment group, PFS was 6 (IC95%: 3-NA) and OS was 15 (IC95%: 6-NA). There were 322 AEs, the most frequent being blood disorders 16% (52), general disorders 12% (38), and gastrointestinal disorders 12% (38). CONCLUSIONS: The median PFS was similar to that reported previously, with lower OS. There was a tendency to achieve better results when eribulin was used earlier. Eribulin is a less well-tolerated drug than published literature.
背景:转移性乳腺癌(MBC)是无法治愈的。全身治疗是标准治疗;然而,一个最佳的化疗顺序尚未确定。目的:评价伊瑞布林治疗MBC的有效性和安全性,并与文献资料进行比较。方法:对2015年12月1日至2021年10月30日接受伊瑞布林治疗的MBC患者进行观察性、描述性和回顾性研究。使用kaplan - meier -生存曲线分析治疗总人数的有效性,并按治疗线分层。以CTCAE v5.0为标准,根据不良事件(AE)进行安全性评价。使用R v4.0.1进行数据分析。结果:本研究纳入53名接受伊瑞布林治疗的女性(中位年龄58岁)。该研究与已发表数据的中位生存期比较为:患者总人数的无进展生存期(PFS) 3 (IC95%: 3 - 4) vs 3.7个月,总生存期(OS) 8 (IC95%: 3 - 4) vs 13.2个月。对于1-3线治疗组,PFS为6 (IC95%: 3-NA), OS为15 (IC95%: 6- na)。共有322例ae,最常见的是血液疾病16%(52例),一般疾病12%(38例),胃肠道疾病12%(38例)。结论:中位PFS与之前报道的相似,OS较低。早期使用伊曲布林有取得更好效果的趋势。与已发表的文献相比,艾里布林是一种耐受性较差的药物。
{"title":"Eribulin in metastatic breast cancer: Real world data","authors":"C. L. Fernández-Laguna, I. Maray, Lola Macia-Rivas, Cristina Álvarez-Asteinza, Sergio Fernández-Lastras, Veronica Velasco Durántez, Mónica Carbajales Álvarez, Ana Lozan-Blázquez","doi":"10.3233/bd-230031","DOIUrl":"https://doi.org/10.3233/bd-230031","url":null,"abstract":"BACKGROUND: Metastatic breast cancer (MBC) is incurable. Systemic therapy is the standard treatment; however, an optimal sequence of chemotherapy has not been established. OBJECTIVE: Evaluating effectiveness and safety of eribulin in MBC treatment and comparing the results obtained with published literature. METHODS: Observational, descriptive and retrospective study of patients with MBC treated with eribulin from 01/12/2015 to 30/10/2021. Effectiveness was analysed using Kaplan–Meier-survival-curves, for the overall number of patients treated and stratified by treatment line. Safety was measured according to adverse events (AE) based on CTCAE v5.0. Data analysis was performed using R v4.0.1. RESULTS: They were included in this study 53 women who received eribulin (median age 58 years). Comparison of median survival from this study versus published data were: progression-free-survival (PFS) 3 (IC95%: 3–4) versus 3.7 months and overall-survival (OS) 8 (IC95%: 3–4) versus 13.2 months for the overall number of patients. For the 1–3 line treatment group, PFS was 6 (IC95%: 3-NA) and OS was 15 (IC95%: 6-NA). There were 322 AEs, the most frequent being blood disorders 16% (52), general disorders 12% (38), and gastrointestinal disorders 12% (38). CONCLUSIONS: The median PFS was similar to that reported previously, with lower OS. There was a tendency to achieve better results when eribulin was used earlier. Eribulin is a less well-tolerated drug than published literature.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138599587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genomic analysis of breast cancer patients from Kerala: A novel BRCA1 mutation detected 喀拉拉邦乳腺癌患者的基因组分析:检测到一种新的BRCA1突变
Pub Date : 2023-11-10 DOI: 10.3233/bd-220002
Adarsh Dharmarajan, Vipin Gopinath, Sangeetha Keloth Nayanar, Sobhith Velandi Kunnummal, Satheesan Balasubramanian, Deepak Roshan Valiyaparambil Gopi
BACKGROUND: Breast cancer is the most common cancer among females, with an incidence of 6,41,000 cases annually. The genetic makeup of the individuals, ethnicity, geographical location, lifestyle, and BMI are some well-described factors associated with breast cancer. It is well known that pathogenic variants in BRCA1 and BRCA2 are associated with a majority of hereditary breast cancer. Genome-wide association studies (GWAS) have identified more than 80 germline susceptibility loci responsible for hereditary breast cancer. METHODS: In the present study, analysis of 94 genes associated with hereditary cancer was performed using next generation sequencing (NGS) in twelve patients having breast cancer and suspected with hereditary association. RESULTS: Four out of twelve (33%) patients harbored pathogenic mutation of the BRCA1 gene. Two patients was identified p. E23Vfs*17 mutation in BRCA1, one patient had p.Glu1580Gln in BRCA1, and a novel frameshift variant p.T1456Ifs*9(c.4367Cdel) in one patient. CONCLUSION: In the present study, out of four detected mutations in the BRCA1 gene, three were known and one was a novel BRCA1 mutation. It is advised to perform NGS-based genome sequencing to identify the genetic predisposition in breast cancer patients.
背景:乳腺癌是女性中最常见的癌症,每年的发病率为641,000例。个体的基因组成、种族、地理位置、生活方式和身体质量指数是与乳腺癌相关的一些很好的因素。众所周知,BRCA1和BRCA2的致病变异与大多数遗传性乳腺癌有关。全基因组关联研究(GWAS)已经确定了80多个与遗传性乳腺癌相关的种系易感位点。方法:采用下一代测序(NGS)对12例疑似有遗传关联的乳腺癌患者进行94个与遗传性癌症相关的基因分析。结果:12例患者中有4例(33%)携带BRCA1基因致病性突变。2例患者在BRCA1中发现p. E23Vfs*17突变,1例患者在BRCA1中发现p. glu1580gln突变,1例患者发现新的移码变体p. t1456ifs *9(c.4367Cdel)。结论:在本研究中,检测到的4个BRCA1基因突变中,有3个是已知的,1个是新的BRCA1突变。建议采用基于ngs的基因组测序来确定乳腺癌患者的遗传易感性。
{"title":"Genomic analysis of breast cancer patients from Kerala: A novel BRCA1 mutation detected","authors":"Adarsh Dharmarajan, Vipin Gopinath, Sangeetha Keloth Nayanar, Sobhith Velandi Kunnummal, Satheesan Balasubramanian, Deepak Roshan Valiyaparambil Gopi","doi":"10.3233/bd-220002","DOIUrl":"https://doi.org/10.3233/bd-220002","url":null,"abstract":"BACKGROUND: Breast cancer is the most common cancer among females, with an incidence of 6,41,000 cases annually. The genetic makeup of the individuals, ethnicity, geographical location, lifestyle, and BMI are some well-described factors associated with breast cancer. It is well known that pathogenic variants in BRCA1 and BRCA2 are associated with a majority of hereditary breast cancer. Genome-wide association studies (GWAS) have identified more than 80 germline susceptibility loci responsible for hereditary breast cancer. METHODS: In the present study, analysis of 94 genes associated with hereditary cancer was performed using next generation sequencing (NGS) in twelve patients having breast cancer and suspected with hereditary association. RESULTS: Four out of twelve (33%) patients harbored pathogenic mutation of the BRCA1 gene. Two patients was identified p. E23Vfs*17 mutation in BRCA1, one patient had p.Glu1580Gln in BRCA1, and a novel frameshift variant p.T1456Ifs*9(c.4367Cdel) in one patient. CONCLUSION: In the present study, out of four detected mutations in the BRCA1 gene, three were known and one was a novel BRCA1 mutation. It is advised to perform NGS-based genome sequencing to identify the genetic predisposition in breast cancer patients.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135190959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Axillary reverse mapping in breast cancer: An overview. 乳腺癌腋窝反向映射:综述。
Pub Date : 2023-01-01 DOI: 10.3233/BD-220040
Yara Abbas, Omar Hamdy

Standard operative management for breast carcinoma has significantly shifted from extensive procedures to minor interventions.Although axillary dissection was a fundamental component of operative management, sentinel biopsy is an actual process for axillary staging. Axillary dissection may be postponed for cases that have negative SLNs or 1 or 2 infiltrated lymph nodes undergoing breast or axillary radiation. Contrarily, axillary dissection is still the conventional management for patients with clinically positive nodes.Arm lymphedema is a frequent and overwhelming complication of axillary dissection, with a worse impact on the patient's life.Axillary reverse mapping was recently introduced to map and conserve the lymph drain of the upper limb throughout axillary dissection or sentinel biopsy. A technique based on the theory that the breast's lymphatic drainage differs from those that drain the arm, so preserving lymphatic drainage of the upper limb can prevent lymphedema, thereby not raising the risk of axillary recurrence.Therefore, this technique is the reverse of sentinel biopsy, which remove the lymph nodes that drain the breast.

乳腺癌的标准手术管理已明显从广泛的手术转向小的干预。虽然腋窝解剖是手术处理的基本组成部分,前哨活检是腋窝分期的实际过程。对于sln阴性或1或2个浸润淋巴结接受乳腺或腋窝放疗的病例,腋窝清扫可推迟进行。相反,腋窝清扫仍然是临床阳性淋巴结患者的常规处理方法。上肢淋巴水肿是腋窝夹层的常见并发症,严重影响患者的生活。腋窝反向测绘最近被引入,通过腋窝解剖或前哨活检来绘制和保存上肢的淋巴引流。一种基于以下理论的技术:乳房的淋巴引流与手臂的淋巴引流不同,因此保留上肢的淋巴引流可以预防淋巴水肿,从而不会增加腋窝复发的风险。因此,这项技术与前哨活检相反,后者切除了乳腺的淋巴结。
{"title":"Axillary reverse mapping in breast cancer: An overview.","authors":"Yara Abbas,&nbsp;Omar Hamdy","doi":"10.3233/BD-220040","DOIUrl":"https://doi.org/10.3233/BD-220040","url":null,"abstract":"<p><p>Standard operative management for breast carcinoma has significantly shifted from extensive procedures to minor interventions.Although axillary dissection was a fundamental component of operative management, sentinel biopsy is an actual process for axillary staging. Axillary dissection may be postponed for cases that have negative SLNs or 1 or 2 infiltrated lymph nodes undergoing breast or axillary radiation. Contrarily, axillary dissection is still the conventional management for patients with clinically positive nodes.Arm lymphedema is a frequent and overwhelming complication of axillary dissection, with a worse impact on the patient's life.Axillary reverse mapping was recently introduced to map and conserve the lymph drain of the upper limb throughout axillary dissection or sentinel biopsy. A technique based on the theory that the breast's lymphatic drainage differs from those that drain the arm, so preserving lymphatic drainage of the upper limb can prevent lymphedema, thereby not raising the risk of axillary recurrence.Therefore, this technique is the reverse of sentinel biopsy, which remove the lymph nodes that drain the breast.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9431293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pseudoangiomatous stromal hyperplasia of the breast, imaging and clinical perspective: A review. 乳腺假性血管瘤间质增生、影像学及临床研究进展。
Pub Date : 2023-01-01 DOI: 10.3233/BD-220072
Afsaneh Alikhassi, Mia Skarpathiotakis, Fang-L Lu, Belinda Curpen

Pseudoangiomatous stromal hyperplasia (PASH) is a benign breast pathology, which most commonly presents incidentally along with other breast pathologies. The etiology and pathogenesis of PASH are still unknown; however, there is some evidence suggesting PASH is hormone dependent. The clinical history, presentation, and imaging appearance of PASH are variable. Clinically, PASH has a wide spectrum of presentations, from being silent to gigantomastia. On imaging, PASH demonstrates various benign to suspicious features. Here we summarize PASH's clinical presentation, histopathology, imaging features, and management.

假性血管瘤间质增生(PASH)是一种良性乳腺病理,通常与其他乳腺病理同时出现。PASH的病因和发病机制尚不清楚;然而,有证据表明PASH依赖于激素。PASH的临床病史、表现和影像学表现各不相同。临床上,PASH有广泛的表现,从沉默到巨乳症。在影像学上,PASH表现出各种良性到可疑的特征。在此,我们总结PASH的临床表现、组织病理学、影像学特征和治疗。
{"title":"Pseudoangiomatous stromal hyperplasia of the breast, imaging and clinical perspective: A review.","authors":"Afsaneh Alikhassi,&nbsp;Mia Skarpathiotakis,&nbsp;Fang-L Lu,&nbsp;Belinda Curpen","doi":"10.3233/BD-220072","DOIUrl":"https://doi.org/10.3233/BD-220072","url":null,"abstract":"<p><p>Pseudoangiomatous stromal hyperplasia (PASH) is a benign breast pathology, which most commonly presents incidentally along with other breast pathologies. The etiology and pathogenesis of PASH are still unknown; however, there is some evidence suggesting PASH is hormone dependent. The clinical history, presentation, and imaging appearance of PASH are variable. Clinically, PASH has a wide spectrum of presentations, from being silent to gigantomastia. On imaging, PASH demonstrates various benign to suspicious features. Here we summarize PASH's clinical presentation, histopathology, imaging features, and management.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9431296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality assessment of breast cancer studies conducted with the Delphi technique. 用德尔菲技术对乳腺癌研究进行质量评估。
Pub Date : 2023-01-01 DOI: 10.3233/BD-220079
Daniela Patino-Hernandez, Daniel G Fernández-Ávila, Óscar Mauricio Muñoz-Velandia, Isabel Del Socorro Moreno Luna

Background: The Delphi technique is a consensus method aiming to obtain statistical estimations from a qualitative approach, through an iterative process that leads to consensus within experts. The main characteristics of the technique include iteration, anonymity, feedback, and consensus reaching. When high-quality, quantitative evidence on a particular topic is insufficient, the Delphi technique can be used for making decisions in clinical scenarios. However, the quality of studies on breast cancer conducted with this technique, has not been assessed.

Objective: We aim to evaluate the quality of studies on breast cancer which used the Delphi technique as their method.

Methods: A quality assessment tool (Quali-D) was created through consensus among experts on the Delphi technique. Then, the tool was applied to studies on breast cancer which used the Delphi technique as their method.

Results: Studies conducted through the Delphi technique mainly assessed for quality indicators and expressed needs in patients with breast cancer. High-quality characteristics were reported in 63.89% of the studies. 98.61% used the Delphi technique due to lack of a more adequate method to solve their research question. 98.61% summarized and presented results in a clear way. In 91.67% of the studies, at least two rounds were conducted. 86.11% described the methods for expert selection in a complete manner. Only 54.17% of the studies reported an anonymous process and 4.17% of the studies disclosed conflicts of interest thoroughly.

Conclusions: A variety of topics were assessed through the Delphi technique in cases where no other technique would have been more appropriate for assessing these issues. Significant limitations are present in terms of anonymity and full disclosure of conflicts of interest. We found that the quality of studies conducted with the Delphi technique regarding breast cancer is overall good. However, the limitations of each study must be considered when applying their results to clinical practice.

背景:德尔菲技术是一种共识方法,旨在通过迭代过程从定性方法中获得统计估计,从而在专家内部达成共识。该技术的主要特点包括迭代、匿名、反馈和达成共识。当某一特定主题的高质量、定量证据不足时,德尔菲技术可用于在临床场景中做出决策。然而,用这种技术进行的乳腺癌研究的质量尚未得到评估。目的:评价用德尔菲法进行乳腺癌研究的质量。方法:采用德尔菲法,经专家协商一致,建立质量评价工具(quality - d)。然后,将该工具应用于以德尔菲技术为方法的乳腺癌研究。结果:通过德尔菲技术进行的研究主要是对乳腺癌患者的质量指标和表达需求进行评估。63.89%的研究报告了高质量特征。由于缺乏一种更充分的方法来解决他们的研究问题,98.61%的人使用德尔菲技术。98.61%对结果进行了清晰的总结和呈现。91.67%的研究至少进行了两轮。86.11%的人完整地描述了专家选择的方法。只有54.17%的研究报告了匿名过程,4.17%的研究彻底披露了利益冲突。结论:在没有其他技术更适合评估这些问题的情况下,通过德尔菲技术评估了各种主题。在匿名和充分披露利益冲突方面存在重大限制。我们发现用德尔菲技术进行的关于乳腺癌的研究质量总体上是好的。然而,在将每项研究的结果应用于临床实践时,必须考虑其局限性。
{"title":"Quality assessment of breast cancer studies conducted with the Delphi technique.","authors":"Daniela Patino-Hernandez,&nbsp;Daniel G Fernández-Ávila,&nbsp;Óscar Mauricio Muñoz-Velandia,&nbsp;Isabel Del Socorro Moreno Luna","doi":"10.3233/BD-220079","DOIUrl":"https://doi.org/10.3233/BD-220079","url":null,"abstract":"<p><strong>Background: </strong>The Delphi technique is a consensus method aiming to obtain statistical estimations from a qualitative approach, through an iterative process that leads to consensus within experts. The main characteristics of the technique include iteration, anonymity, feedback, and consensus reaching. When high-quality, quantitative evidence on a particular topic is insufficient, the Delphi technique can be used for making decisions in clinical scenarios. However, the quality of studies on breast cancer conducted with this technique, has not been assessed.</p><p><strong>Objective: </strong>We aim to evaluate the quality of studies on breast cancer which used the Delphi technique as their method.</p><p><strong>Methods: </strong>A quality assessment tool (Quali-D) was created through consensus among experts on the Delphi technique. Then, the tool was applied to studies on breast cancer which used the Delphi technique as their method.</p><p><strong>Results: </strong>Studies conducted through the Delphi technique mainly assessed for quality indicators and expressed needs in patients with breast cancer. High-quality characteristics were reported in 63.89% of the studies. 98.61% used the Delphi technique due to lack of a more adequate method to solve their research question. 98.61% summarized and presented results in a clear way. In 91.67% of the studies, at least two rounds were conducted. 86.11% described the methods for expert selection in a complete manner. Only 54.17% of the studies reported an anonymous process and 4.17% of the studies disclosed conflicts of interest thoroughly.</p><p><strong>Conclusions: </strong>A variety of topics were assessed through the Delphi technique in cases where no other technique would have been more appropriate for assessing these issues. Significant limitations are present in terms of anonymity and full disclosure of conflicts of interest. We found that the quality of studies conducted with the Delphi technique regarding breast cancer is overall good. However, the limitations of each study must be considered when applying their results to clinical practice.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9431297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Breast disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1